ClinicalTrials.gg
TerminatedNCT02651116CHPA DXMUpdated Apr 28, 2021Results posted

Dextromethorphan Pediatric Acute Cough Study

A Phase 4 interventional study of Dextromethorphan Hydrobromide and Placebo in Cough, sponsored by Pfizer. Terminated at 18 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-04-28.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Why this study was terminated
The study was prematurely discontinued due to slow enrollment during the 2019/2020 cold season. No safety or efficacy concerns led to the decision to terminate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies in Cough with a site in United States — 17 open to participants now, 21 under way, 1 of them phase 3. Cough · United States.

Enrollment
26th of 85
131 · median 65
Started
2016
with 2 others
Phase 4
9 of 103
1 open now
Registered
48th of 103
by date
Lead sponsor
3 of 103
Pfizer

Among the 103 studies in Cough with a site in United States, this one is the 26th largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2016, is one of 9 in phase 4, and was the 48th registered.

Cough

428 studies on the registry are indexed under Cough; 68 are open to participants now.

Browse Cough studies →

Open to participants now

17 of the 103 studies in Cough with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Cough studies recruiting now, 20 (43%) set no upper age limit and 14 (30%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Cough with a site in United States, or all of them as a file.
02

Study summary

This is a placebo-controlled, double-blind, randomized, parallel group pilot study in approximately 150 subjects to evaluate the efficacy of dextromethorphan hydrobromide (DXM) on acute cough in a pediatric population. Subjects will be otherwise healthy males and females aged 6-11 inclusive who are experiencing acute cough as a symptom of common cold or upper respiratory tract infection. Subjects must have had onset of symptoms within 3 days of screening and qualify based on physical exam and symptom questionnaire. Eligible subjects will be given a single-blind placebo, and fitted with a cough counting device for a 2 hour run-in period. Qualifying subjects will be stratified by age and then randomized to either DXM or placebo in a 1:1 ratio and fitted with the cough recording device for the first 24 hours of treatment. Subjects will receive approximately 9 doses of investigational product over the course of the 4 day study and will complete patient reported outcome questions before the morning and afternoon doses. Subjects will return to the study site on Day 2 to remove the cough recorder and on Day 4 (+ 2 days) to complete the final visit. A review of any reported adverse events will also be completed.

Read the detailed description

This is a placebo-controlled, double-blind, randomized, parallel group pilot study in approximately 150 subjects to evaluate the efficacy of dextromethorphan hydrobromide DXM) on acute cough in a pediatric population. Subjects will be otherwise healthy males and females aged 6-11 inclusive who are experiencing acute cough as a symptom of common cold or upper respiratory tract infection. Subjects must have had onset of symptoms within 3 days of screening and qualify based on physical exam and symptom questionnaire. Eligible subjects will be given a single-blind placebo, and fitted with a cough counting device for a 2 hour run-in period. Qualifying subjects will be stratified by age and then randomized to either DXM or placebo in a 1:1 ratio and fitted with the cough recording device for the first 24 hours of treatment. Subjects will receive approximately 9 doses of investigational product over the course of the 4 day study and will complete patient reported outcome questions before the morning and afternoon doses. Subjects will return to the study site on Day 2 to remove the cough recorder and Day 4 (+2 days) to complete the final visit. A review of any reported adverse events will also be completed. Validated Patient Reported Outcomes (PRO) used in the study include morning cough assessment, afternoon cough assessment, Child Global Question, and Child Cold Symptom Checklist

03

Conditions studied

  • Cough

Browse trials for

Keywords

  • cough, acute cough, pediatric, Dextromethorphan Hydrobromide, antitussive, ambulatory cough recording device
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generally healthy male or female children/adolescents ages 6 to 11 years, inclusive.
  • Subject has an acute cough and other symptoms consistent with a common cold/acute upper respiratory tract infection (URTI) diagnosis as deemed by the investigator or qualified designee based on findings from medical history review, full physical examination and vital signs.
  • The onset of symptoms must be no more than 3 days prior to Visit 1, as determined by the subject or parent/legally acceptable representative.
  • Qualifying response on the Child Cold Symptom Checklist.
  • Parent/legally acceptable representative, and subject agrees the subject will not use any other cough or cold treatments during the study.

Exclusion criteria

Exclusion Criteria:

  • A subchronic, or chronic cough due to any condition other than an URTI or common cold as established by the investigator, nurse practitioner, or physician's assistant, in accordance with the American College of Chest Physicians' (ACCP) Guidelines for Diagnosis and Management of Cough. Special attention should be paid to highly prevalent conditions commonly presenting with cough such as asthma, rhinitis, or gastroesophageal reflux disease (GERD).
  • Symptoms of runny nose, stuffy nose, sore throat, or sneezing due to any condition other than URTI or common cold (eg, seasonal or perennial allergic rhinitis, sinusitis, strep throat, vasomotor rhinitis, etc.) as established by the investigator.
  • An acute cough that occurs with excessive phlegm (mucus) or is chronic such as occurs with smoking, asthma, bronchitis, allergies, or a gastroesophageal condition (eg, acid reflux and GERD) or history of such a cough.
  • Clinical features of a complication of the common cold during the physical examination at screening (eg, otitis media, sinusitis, or pneumonia) with or without the need for systematic antibiotics.
  • Pneumonia (active or with a symptom-free period of \<30 days), asthma (active or with a symptom-free period of \<1 year), or other significant pulmonary diseases.
  • Fever greater than 39ºC (102ºF oral temperature) at the time of screening if, in the judgment of the investigator, the individual is too ill to participate in the study or the fever is due to reasons other than URTI.
  • Signs of dehydration (as may be due to vomiting, diarrhea, or lack of fluid intake) during the physical examination at screening.
  • Diabetes or hypoglycemic disorders.
  • Known to the product or acetaminophen (APAP).
  • Sitting blood pressure reading at or above the limits as documented in the protocol.
  • Obstructive sleep apnea caused by enlarged tonsils and adenoids, low muscle tone, or allergies.
  • History of known or suspected allergy or to dextromethorphan (DXM) or APAP, or any of the non medicinal ingredients contained in the single-blind confection, double-blind investigational products, or APAP.
  • History of taking any of the specified prohibited medications or products within the corresponding prior to taking the first dose of investigational product.
  • History of taking a medication that is sedating within the past 24 hours prior to screening (eg sedatives, hypnotics, tranquilizers, anticonvulsants, benzodiazepines, and clonidine).
  • Subject has a sibling contemporaneously participating in this study.

Randomization Criteria:

  • Subjects must complete the 2 hour ambulatory cough counting baseline run-in recording period and must return to the study site for randomization at least 2 hours after the recording started.
  • Subjects whose equipment failed, preventing collection of cough count data for at least 2 hours during the Baseline Run-in Period, or those who took off the device during this period will be excluded from further study participation.
  • Subjects who do not return to the study site (before 3:30 pm) in time for the afternoon dose will not be randomized.
  • Qualifying response on Child Global Question
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Dextromethorphan Hydrobromide

    15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide

    Drug: Dextromethorphan Hydrobromide · Device: Cough recording device

  • Placebo comparator
    Placebo

    10 mL of Placebo

    Drug: Placebo · Device: Cough recording device

Interventions

  • 15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide

    Also known as: DXM

  • DrugPlacebo

    10 mL Placebo

  • DeviceCough recording device

    FDA approved device validated for use in adults and children

    Also known as: VitaloJAK

06

What researchers measure

Primary outcomes

  1. Mean of Total Cough Counts: Over 24 Hours Post-First Dose on Day 1

    Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.

    Time frame: Over for 24 hours post-first dose on Day 1

Secondary outcomes

  1. Mean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 1

    Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.

    Time frame: Between Dose 1 to Dose 2 on Day 1

  2. Mean of Total Cough Counts: Between Dose 2 on Day 1 to Dose 3 on Day 2

    Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.

    Time frame: Between Dose 2 on Day 1 to Dose 3 on Day 2 (second dose of Day 1 to first dose of Day 2)

  3. Mean of Total Cough Counts: Between Dose 3 to Dose 4 on Day 2

    Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.

    Time frame: Between Dose 3 to Dose 4 on Day 2 (between first and second dose of Day 2)

  4. Mean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 1, and Between Dose 3 to Dose 4 on Day 2

    Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts. In this outcome measure, as planned combined data is reported for first dosing interval (Dose 1 to Dose 2) on Day 1 and first dosing interval (Dose 3 to Dose 4) on Day 2.

    Time frame: Duration between Dose 1 to Dose 2 on Day 1 (between first and second dose of Day 1) plus duration between Dose 3 to Dose 4 on Day 2 (between first and second dose of Day 2)

  5. Mean of Total Cough Time Accumulated Over a 24-Hour Period Post-First Dose on Day 1

    Time (in seconds) accumulated over a 24-hour period when cough events occurred was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated total cough time accumulated.

    Time frame: Over for 24 hours post-first dose on Day 1

Other outcomes

  1. Change From Baseline in Morning Cough Frequency Assessed in Morning at Day 2, 3, and 4

    Participants on specified time points were asked to respond to the following question: "from when you woke up this morning until now, how much have you been coughing", on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated higher frequency of cough in morning time.

    Time frame: Baseline (morning screening visit on Day 1); Within 30 minutes of waking, before morning dose on Days 2, 3, and 4

  2. Change From Baseline in Morning Cough Severity Assessed in Morning at Day 2, 3, and 4

    Participants on specified time points were asked to respond to the following question: "how bad is your cough this morning", on a 5-point scale: 0= no cough, 1= a tiny bit bad, 2= a little bad, 3= bad and 4= very bad. Higher scores indicated more severe cough in morning time.

    Time frame: Baseline (morning screening visit on Day 1); Within 30 minutes of waking, before morning dose on Days 2, 3, and 4

  3. Change From Baseline in Impact of Cough on Sleep Assessed in Morning at Day 2, 3, and 4

    Participants on specified time points were asked to respond to the following question: "last night in bed, how much did your cough keep you awake", on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated worse impact of cough on sleep.

    Time frame: Baseline (morning screening visit on Day 1); Within 30 minutes of waking, before morning dose on Days 2, 3, and 4

  4. Change From Baseline in Afternoon Cough Frequency Assessed at Afternoon on Day 2, 3, and 4

    Participants on specified time points were asked to respond to the following question: "how much have you been coughing this afternoon" on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated higher frequency of cough in afternoon time.

    Time frame: Baseline (afternoon visit on Day 1 before first dose); Before the afternoon dose on Day 2, and 3; Anytime in afternoon of Day 4

  5. Change From Baseline in Afternoon Cough Severity Assessed at Afternoon on Day 2, 3, and 4

    Participants on specified time points were asked to respond to the following question: "how bad is your cough this afternoon" on a 5-point scale: 0= no cough, 1= a tiny bit bad, 2= a little bad, 3= bad and 4= very bad. Higher scores indicated more severe cough in afternoon time.

    Time frame: Baseline (afternoon visit on Day 1 before first dose); Before the afternoon dose on Day 2, and 3; Anytime in afternoon of Day 4

  6. Change From Baseline in Child Global Question Assessed at Afternoon on Day 2, 3, and 4

    Participants on specified time points were asked to respond to the following question: "how bad is your cold today", on a 5-point scale; 0= no cold, 1= a tiny bit bad, 2= a little bad, 3= bad, and 4= very bad. Higher scores indicated worse cold.

    Time frame: Baseline (afternoon visit on Day 1 before first dose); Before the afternoon dose on Day 2, and 3; Anytime in afternoon of Day 4

  7. Pediatric Global Assessment of Satisfaction With Study Medication: By Participant, and Caregiver

    Participants at the end of the study were asked to respond to the following question: "How would you rate the study medication for taking away your cough?" on a 7-point scale: 0= excellent, 1= very good, 2= good, 3= fair, 4= poor, 5= very poor, and 6= terrible. Higher scores indicated poorer satisfaction with study medication. Within 20 minutes after participants completed the assessment parents/legally acceptable representative were asked to respond to the question: "How would you rate the study medication for taking away your child's cough?" on a 7-point scale: 0= excellent, 1= very good, 2= good, 3= fair, 4= poor, 5= very poor, and 6= terrible. Higher scores indicated poorer satisfaction with study medication.

    Time frame: For participants: at the end of the study on Day 4; For parents/legally acceptable representatives: within 20 minutes after participant completed assessment at the end of the study on Day 4

07

Results

Posted Apr 28, 2021

Participant flow

Study was conducted in the United States from 25 February 2016 to 19 March 2020.

Participant flow — Overall Study
MilestoneDextromethorphan HydrobromidePlacebo
Started6863
Treated6863
Completed6762
Not completed11
Withdrew: Adverse event01
Withdrew: No longer willing to participate in study10

Outcome measures

PrimaryMean of Total Cough Counts: Over 24 Hours Post-First Dose on Day 1

Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.

Time frame:
Over for 24 hours post-first dose on Day 1
Reported as:
Mean · cough counts
Mean of Total Cough Counts: Over 24 Hours Post-First Dose on Day 1
cough countsDextromethorphan HydrobromidePlacebo
Mean of Total Cough Counts: Over 24 Hours Post-First Dose on Day 1457.1 ± 367.21676.8 ± 814.33
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · Negative Binomial Regression · p = 0.0449 (P-Value less than or equal to (\<=) 0.05 level was considered significantly better and P-Value lying between 0.05 less than (\<) p\<=0.1 level was considered marginally significantly better.) · Rate ratio: 0.7899 · 95% CI 0.6273 to 0.9947
  • Dextromethorphan Hydrobromide vs Placebo · Negative Binomial Regression · p = 0.6293 (P-value is for interaction term of treatment by age group. P-value \<=0.10 was considered significant for interaction terms.)
SecondaryMean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 1

Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.

Time frame:
Between Dose 1 to Dose 2 on Day 1
Reported as:
Mean · cough counts
Mean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 1
cough countsDextromethorphan HydrobromidePlacebo
Mean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 132.73 ± 30.59747.03 ± 57.729
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · Negative Binomial Regression · p = 0.0552 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Rate ratio: 0.8048 · 95% CI 0.6446 to 1.0049
SecondaryMean of Total Cough Counts: Between Dose 2 on Day 1 to Dose 3 on Day 2

Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.

Time frame:
Between Dose 2 on Day 1 to Dose 3 on Day 2 (second dose of Day 1 to first dose of Day 2)
Reported as:
Mean · cough counts
Mean of Total Cough Counts: Between Dose 2 on Day 1 to Dose 3 on Day 2
cough countsDextromethorphan HydrobromidePlacebo
Mean of Total Cough Counts: Between Dose 2 on Day 1 to Dose 3 on Day 29.70 ± 8.87711.44 ± 13.193
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · Negative Binomial Regression · p = 0.7684 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Rate ratio: 0.9551 · 95% CI 0.7032 to 1.2971
SecondaryMean of Total Cough Counts: Between Dose 3 to Dose 4 on Day 2

Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts.

Time frame:
Between Dose 3 to Dose 4 on Day 2 (between first and second dose of Day 2)
Reported as:
Mean · cough counts
Mean of Total Cough Counts: Between Dose 3 to Dose 4 on Day 2
cough countsDextromethorphan HydrobromidePlacebo
Mean of Total Cough Counts: Between Dose 3 to Dose 4 on Day 219.32 ± 16.75233.62 ± 47.709
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · Negative Binomial Regression · p = 0.0220 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Rate ratio: 0.7014 · 95% CI 0.5178 to 0.9500
SecondaryMean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 1, and Between Dose 3 to Dose 4 on Day 2

Total cough count was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated cough counts. In this outcome measure, as planned combined data is reported for first dosing interval (Dose 1 to Dose 2) on Day 1 and first dosing interval (Dose 3 to Dose 4) on Day 2.

Time frame:
Duration between Dose 1 to Dose 2 on Day 1 (between first and second dose of Day 1) plus duration between Dose 3 to Dose 4 on Day 2 (between first and second dose of Day 2)
Reported as:
Mean · cough counts
Mean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 1, and Between Dose 3 to Dose 4 on Day 2
cough countsDextromethorphan HydrobromidePlacebo
Mean of Total Cough Counts: Between Dose 1 to Dose 2 on Day 1, and Between Dose 3 to Dose 4 on Day 226.13 ± 21.49840.39 ± 49.896
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · Negative Binomial Regression · p = 0.0098 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Rate ratio: 0.7454 · 95% CI 0.5964 to 0.9316
SecondaryMean of Total Cough Time Accumulated Over a 24-Hour Period Post-First Dose on Day 1

Time (in seconds) accumulated over a 24-hour period when cough events occurred was collected by the cough recording device VitaloJAKTM in an ambulatory setting. The VitaloJAKTM device recorded continuous digital audio obtained through both a lapel microphone clipped to the participant's clothing at the neck or upper chest level, and a chest wall sensor attached to the participant's chest at the top of the sternum. Data was captured on a data card and the vitalograph analyst evaluated total cough time accumulated.

Time frame:
Over for 24 hours post-first dose on Day 1
Reported as:
Mean · seconds
Mean of Total Cough Time Accumulated Over a 24-Hour Period Post-First Dose on Day 1
secondsDextromethorphan HydrobromidePlacebo
Mean of Total Cough Time Accumulated Over a 24-Hour Period Post-First Dose on Day 1350.5 ± 268.95502.7 ± 566.57
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · ANCOVA · p = 0.0977 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Difference in least squares mean: -0.2210 · 95% CI -0.4831 to 0.0411
Other pre-specifiedChange From Baseline in Morning Cough Frequency Assessed in Morning at Day 2, 3, and 4

Participants on specified time points were asked to respond to the following question: "from when you woke up this morning until now, how much have you been coughing", on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated higher frequency of cough in morning time.

Time frame:
Baseline (morning screening visit on Day 1); Within 30 minutes of waking, before morning dose on Days 2, 3, and 4
Reported as:
Mean · units on a scale
Change From Baseline in Morning Cough Frequency Assessed in Morning at Day 2, 3, and 4
units on a scaleDextromethorphan HydrobromidePlacebo
Baseline3.4 ± 0.653.3 ± 0.63
Change at Day 2-1.2 ± 1.30-0.7 ± 1.15
Change at Day 3-1.5 ± 1.15-1.1 ± 1.38
Change at Day 4-2.0 ± 1.20-1.8 ± 1.40
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.0191 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Difference in least squares mean: -0.2881 · 95% CI -0.5287 to -0.0475
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.8355 (P-value is for interaction term of treatment by age group. P-value \<=0.10 was considered significant for interaction terms.)
Other pre-specifiedChange From Baseline in Morning Cough Severity Assessed in Morning at Day 2, 3, and 4

Participants on specified time points were asked to respond to the following question: "how bad is your cough this morning", on a 5-point scale: 0= no cough, 1= a tiny bit bad, 2= a little bad, 3= bad and 4= very bad. Higher scores indicated more severe cough in morning time.

Time frame:
Baseline (morning screening visit on Day 1); Within 30 minutes of waking, before morning dose on Days 2, 3, and 4
Reported as:
Mean · units on a scale
Change From Baseline in Morning Cough Severity Assessed in Morning at Day 2, 3, and 4
units on a scaleDextromethorphan HydrobromidePlacebo
Baseline3.1 ± 0.543.1 ± 0.60
Change at Day 2-1.1 ± 0.89-0.6 ± 1.19
Change at Day 3-1.4 ± 0.96-1.3 ± 1.22
Change at Day 4-1.9 ± 1.10-1.8 ± 1.15
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.0049 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Difference in least squares mean: -0.3128 · 95% CI -0.5299 to -0.0956
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.8413 (P-value is for interaction term of treatment by age group. P-value \<=0.10 was considered significant for interaction terms.)
Other pre-specifiedChange From Baseline in Impact of Cough on Sleep Assessed in Morning at Day 2, 3, and 4

Participants on specified time points were asked to respond to the following question: "last night in bed, how much did your cough keep you awake", on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated worse impact of cough on sleep.

Time frame:
Baseline (morning screening visit on Day 1); Within 30 minutes of waking, before morning dose on Days 2, 3, and 4
Reported as:
Mean · units on a scale
Change From Baseline in Impact of Cough on Sleep Assessed in Morning at Day 2, 3, and 4
units on a scaleDextromethorphan HydrobromidePlacebo
Baseline2.8 ± 1.153.0 ± 1.19
Change at Day 2-0.8 ± 1.56-0.7 ± 1.45
Change at Day 3-1.3 ± 1.59-1.4 ± 1.67
Change at Day 4-1.8 ± 1.57-1.9 ± 1.74
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.2679 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Difference in least squares mean: -0.1483 · 95% CI -0.4112 to 0.1146
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.2882 (P-value is for interaction term of treatment by age group. P-value \<=0.10 was considered significant for interaction terms.)
Other pre-specifiedChange From Baseline in Afternoon Cough Frequency Assessed at Afternoon on Day 2, 3, and 4

Participants on specified time points were asked to respond to the following question: "how much have you been coughing this afternoon" on a 5-point scale: 0= not at all, 1= a tiny bit, 2= a little, 3= some and 4= a lot. Higher scores indicated higher frequency of cough in afternoon time.

Time frame:
Baseline (afternoon visit on Day 1 before first dose); Before the afternoon dose on Day 2, and 3; Anytime in afternoon of Day 4
Reported as:
Mean · units on a scale
Change From Baseline in Afternoon Cough Frequency Assessed at Afternoon on Day 2, 3, and 4
units on a scaleDextromethorphan HydrobromidePlacebo
Baseline3.2 ± 0.803.4 ± 0.73
Change at Day 2-0.7 ± 1.25-0.6 ± 1.06
Change at Day 3-1.5 ± 1.30-1.4 ± 1.27
Change at Day 4-1.9 ± 1.22-1.8 ± 1.41
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.0242 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Difference in least squares mean: -0.2812 · 95% CI -0.5255 to -0.0369
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.2892 (P-value is for interaction term of treatment by age group. P-value \<=0.10 was considered significant for interaction terms.)
Other pre-specifiedChange From Baseline in Afternoon Cough Severity Assessed at Afternoon on Day 2, 3, and 4

Participants on specified time points were asked to respond to the following question: "how bad is your cough this afternoon" on a 5-point scale: 0= no cough, 1= a tiny bit bad, 2= a little bad, 3= bad and 4= very bad. Higher scores indicated more severe cough in afternoon time.

Time frame:
Baseline (afternoon visit on Day 1 before first dose); Before the afternoon dose on Day 2, and 3; Anytime in afternoon of Day 4
Reported as:
Mean · units on a scale
Change From Baseline in Afternoon Cough Severity Assessed at Afternoon on Day 2, 3, and 4
units on a scaleDextromethorphan HydrobromidePlacebo
Baseline2.8 ± 0.833.1 ± 0.84
Change at Day 2-0.7 ± 1.16-0.6 ± 0.98
Change at Day 3-1.4 ± 1.15-1.4 ± 1.24
Change at Day 4-1.7 ± 1.08-1.6 ± 1.45
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.0063 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Difference in least squares mean: -0.3014 · 95% CI -0.5170 to -0.0858
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.3268 (P-value is for interaction term of treatment by age group. P-value \<=0.10 was considered significant for interaction terms.)
Other pre-specifiedChange From Baseline in Child Global Question Assessed at Afternoon on Day 2, 3, and 4

Participants on specified time points were asked to respond to the following question: "how bad is your cold today", on a 5-point scale; 0= no cold, 1= a tiny bit bad, 2= a little bad, 3= bad, and 4= very bad. Higher scores indicated worse cold.

Time frame:
Baseline (afternoon visit on Day 1 before first dose); Before the afternoon dose on Day 2, and 3; Anytime in afternoon of Day 4
Reported as:
Mean · units on a scale
Change From Baseline in Child Global Question Assessed at Afternoon on Day 2, 3, and 4
units on a scaleDextromethorphan HydrobromidePlacebo
Baseline3.2 ± 0.423.3 ± 0.46
Change at Day 2-1.1 ± 1.02-0.9 ± 1.01
Change at Day 3-1.6 ± 0.93-1.6 ± 1.13
Change at Day 4-2.1 ± 0.87-1.7 ± 1.26
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.0247 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Difference in least squares mean: -0.2535 · 95% CI -0.4745 to -0.0325
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.4093 (P-value is for interaction term of treatment by age group. P-value \<=0.10 was considered significant for interaction terms.)
Other pre-specifiedPediatric Global Assessment of Satisfaction With Study Medication: By Participant, and Caregiver

Participants at the end of the study were asked to respond to the following question: "How would you rate the study medication for taking away your cough?" on a 7-point scale: 0= excellent, 1= very good, 2= good, 3= fair, 4= poor, 5= very poor, and 6= terrible. Higher scores indicated poorer satisfaction with study medication. Within 20 minutes after participants completed the assessment parents/legally acceptable representative were asked to respond to the question: "How would you rate the study medication for taking away your child's cough?" on a 7-point scale: 0= excellent, 1= very good, 2= good, 3= fair, 4= poor, 5= very poor, and 6= terrible. Higher scores indicated poorer satisfaction with study medication.

Time frame:
For participants: at the end of the study on Day 4; For parents/legally acceptable representatives: within 20 minutes after participant completed assessment at the end of the study on Day 4
Reported as:
Mean · units on a scale
Pediatric Global Assessment of Satisfaction With Study Medication: By Participant, and Caregiver
units on a scaleDextromethorphan HydrobromidePlacebo
By Participant:1.7 ± 1.201.6 ± 1.26
By Caregiver:1.8 ± 1.071.9 ± 1.16
Statistical analysis
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.5652 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Difference in least squares mean: 0.1266 · 95% CI -0.3081 to 0.5614
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.4914 (P-Value \<=0.05 level was considered significantly better and P-Value lying between 0.05\<p\<=0.1 level was considered marginally significantly better.) · Difference in least squares mean: -0.1368 · 95% CI -0.5292 to 0.2556
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.1029 (P-value is for interaction term of treatment by age group. P-value \<=0.10 was considered significant for interaction terms.)
  • Dextromethorphan Hydrobromide vs Placebo · ANOVA · p = 0.4736 (P-value is for interaction term of treatment by age group. P-value \<=0.10 was considered significant for interaction terms.)

Adverse events

Collected over Day 1 up to 14 days after last dose of study medication (up to 18 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dextromethorphan Hydrobromide0/68 (0%)0/68 (0%)13/68 (19.1%)
Placebo0/63 (0%)0/63 (0%)16/63 (25.4%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventDextromethorphan HydrobromidePlacebo
HeadacheNervous system disorders1/683/63
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/683/63
Nasal turbinate abnormalityRespiratory, thoracic and mediastinal disorders3/681/63
Otitis mediaInfections and infestations0/682/63
Upper-airway cough syndromeRespiratory, thoracic and mediastinal disorders0/682/63
Dennie-Morgan foldSkin and subcutaneous tissue disorders2/680/63
LymphadenopathyBlood and lymphatic system disorders1/681/63
Lip dryGastrointestinal disorders0/681/63
MalaiseGeneral disorders0/681/63
BronchiolitisInfections and infestations0/681/63

Baseline characteristics

The safety analysis set included all participants who received the study drug.

Age, Continuous
Age, Continuous(Years)Dextromethorphan HydrobromidePlaceboTotal
Mean8.3 ± 1.578.0 ± 1.738.2 ± 1.65
Sex: Female, Male
Sex: Female, Male(Participants)Dextromethorphan HydrobromidePlaceboTotal
Female353267
Male333164
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dextromethorphan HydrobromidePlaceboTotal
Hispanic or Latino4711
Not Hispanic or Latino6456120
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dextromethorphan HydrobromidePlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American242246
White403979
More than one race426
Unknown or Not Reported000
08

Study locations

18 sites
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Clinical Associates of Orlando LLC
    Orlando, Florida 32806, United States
  • Elite Clinical Trials LLLP
    Blackfoot, Idaho 83221, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Kentucky Pediatric/Adult Research
    Bardstown, Kentucky 40004, United States
  • All Children Pediatrics
    Louisville, Kentucky 40243, United States
  • Bluegrass Clinical Research, Inc
    Louisville, Kentucky 40291, United States
  • MedPharmics, LLC
    Metairie, Louisiana 70006, United States
  • Midwest Children's Health Research Institute
    Lincoln, Nebraska 68504, United States
  • Meridian Clinical Research LLC
    Omaha, Nebraska 68134, United States
  • Rapid Medical Research, Inc
    Cleveland, Ohio 44122, United States
  • Coastal Pediatric Associates
    Charleston, South Carolina 29414, United States
  • Coastal Pediatric Associates
    Mount Pleasant, South Carolina 29464, United States
  • Carolina Ear, Nose & Throat Clinic/CENTRI Inc.
    Orangeburg, South Carolina 29118, United States
  • Meridian Clinical Research, LLC
    Dakota Dunes, South Dakota 57049, United States
  • Texas Health Care, PLLC
    Fort Worth, Texas 76104, United States
  • Ventavia Research Group, LLC
    Fort Worth, Texas 76104, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Mar 2020, 48 months.

Results were first posted in Apr 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2016
First posted
Jan 8, 2016
StartActual
Feb 25, 2016
Primary completionActual
Mar 19, 2020
CompletionActual
Mar 19, 2020
Results first posted
Apr 28, 2021
Last update
Apr 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02651116
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 8, 2016
Start date
Feb 25, 2016
Primary completion
Mar 19, 2020
Completion
Mar 19, 2020
Results posted
Apr 28, 2021
Last update
Apr 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan

Start the discussion